Neuraptive Therapeutics, Inc., a biotech startup based in Colorado and Pennsylvania, raised $11.5 million in a Series A funding round led by New Rhein Healthcare Investors LLC LAFAYETTE, Colo., December 19, 2018-- Neuraptive Therapeutics, Inc. (Neuraptive) announced today that it has secured a $11.5 million Series A equity financing which remains open for additional investors. The round was led by New Rhein Healthcare Investors LLC (New Rhein). The Company will use the funds to further develop its flagship product, the AxoFuse Nerve Repair System (AxoFuse™), in clinical trials and to expand operations.